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Abstract Rho-associated kinases 1 and 2 (ROCK1/2) are Rho-GTPase effectors that control key
aspects of the actin cytoskeleton, but their role in proliferation and cancer initiation or progression
is not known. Here, we provide evidence that ROCK1 and ROCK2 act redundantly to maintain
actomyosin contractility and cell proliferation and that their loss leads to cell-cycle arrest and
cellular senescence. This phenotype arises from down-regulation of the essential cell-cycle proteins
CyclinA, CKS1 and CDK1. Accordingly, while the loss of either Rock1 or Rock2 had no negative
impact on tumorigenesis in mouse models of non-small cell lung cancer and melanoma, loss of both
blocked tumor formation, as no tumors arise in which both Rock1 and Rock2 have been genetically
deleted. Our results reveal an indispensable role for ROCK, yet redundant role for isoforms 1 and
2, in cell cycle progression and tumorigenesis, possibly through the maintenance of cellular
contractility.
DOI: 10.7554/eLife.12203.001
Introduction
The Rho-associated coiled-coil-containing protein serine/threonine kinases ROCK1 and ROCK2 are
downstream effectors of the Rho subfamily of small GTPases. They are activated by interaction with
Rho GTPases and act through a number of pathways to regulate the actin cytoskeleton and thus cell
migration, cell-cell adhesion and cancer cell invasion (Itoh et al., 1999; Olson and Sahai, 2009;
Thumkeo et al., 2013). Substrates for ROCKs include the myosin-binding subunit of myosin phos-
phatase (MYPT1) and the myosin regulatory light chain (MLC), which regulate actomyosin contractile
forces (Kawano et al., 1999; Kureishi et al., 1997). Actomyosin contractility is generated when
myosin regulatory light chain (MLC) is phosphorylated, allowing myosin II interaction with actin fila-
ments to generate mechanical force (Aksoy et al., 1983; Kureishi et al., 1997). ROCKs may either
directly phosphorylate MLC (Amano et al., 1996) or indirectly regulate MLC phosphorylation by
phosphorylating the myosin-binding subunit of myosin phosphatase (MYPT1) and inactivating it
(Kimura et al., 1996). Myosin phosphatase inactivation results from phosphorylation of two inhibi-
tory sites, Thr696 and Thr850, on MYPT1 (Feng et al., 1999; Kawano et al., 1999; Muranyi et al.,
2005). Furthermore, ROCKs phosphorylate and activate LIM kinases 1 and 2 (LIMK1, 2), which inhibit
the actin-depolymerizing protein Cofilin (Yang et al., 1998). ROCK1 and 2 exhibit 65% overall iden-
tity and 87% within the kinase domain, and some studies suggest differential roles for the isoforms.
Using RNA interference, ROCK1 was reported to be important for stress fiber formation in fibro-
blasts, whereas ROCK2 controls cortical contractility and phagocytosis (Yoneda et al., 2005;
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2007). Distinct roles for ROCK1 and 2 have also been described in the regulation of keratinocyte dif-
ferentiation (Lock and Hotchin, 2009) and cell detachment (Shi et al., 2013).
Mice in which Rock1 has been genetically deleted are born, but have defects in eyelid as well as
ventral body wall closure (Shimizu et al., 2005). Ninety percent of Rock2 null mice die in utero due
to defects in the placental labyrinth layer. This indicates that ROCK1 cannot compensate for a loss
of ROCK2. However, the few Rock2 null mice, that are born, display defects similar to those
described in Rock1 null mice (Thumkeo et al., 2003). This indicates some level of functional redun-
dancy (Thumkeo et al., 2005). In addition to their role in cell migration, ROCKs have been reported
to modulate apoptosis (Coleman et al., 2001; Sebbagh et al., 2005) and cell proliferation
(Croft and Olson, 2006; Samuel et al., 2011; Zhang et al., 2009). The precise role of ROCKs in cell
proliferation is not clear: some reports suggest ROCK function is required for G1/S progression
(Croft and Olson, 2006; Zhang et al., 2009), but others suggest ROCK is only required for anchor-
age-independent growth of transformed cells (Sahai et al., 1999; Vigil et al., 2012). One in
vivo study reported that over-activation of ROCK, by expressing the kinase domain of ROCK2 in
mouse skin, led to hyperproliferation and epidermal thickening (Samuel et al., 2011). In order to
investigate the roles of ROCK1 and 2 in tumorigenesis, we have generated conditional Rock1 and 2
knockout mice and studied these in vivo, using genetically engineered mouse models of non-small
cell lung cancer (NSCLC) and BrafV600E mutant models of melanoma, as well as in vitro, using cells
isolated from these mice.
Results
Depletion of both ROCK1 and 2 leads to multi-stage cell cycle arrest
through defects in actomyosin contractility
It is well understood that ROCKs control key aspects of the actin cytoskeleton such as actomyosin
contractility, but their role in cell proliferation is not known. Because Rock null mice die early due to
developmental defects, we generated Rock1 and 2 conditional alleles (Rock1f and Rock2f) by
eLife digest Animal cells contain a structure called the cytoskeleton, which helps give the cells
their shape. This structure can rapidly disassemble and reassemble, which enables cells to change
their shape, move and divide into two. Many proteins are involved in controlling these processes. In
particular, two proteins called ROCK1 and ROCK2 are known to be important for helping cancer
cells move. However, investigations into the exact roles of these proteins have so far produced
contradictory results.
Ku¨mper et al. have now developed a more refined method of studying what ROCK1 and ROCK2
do in cells. This involves genetically engineering mice in a way that makes it possible to control
whether ROCK1 and ROCK2 are produced in specific cell types and tissues. Studying cells that had
been taken from these mice revealed that cells that lacked both proteins could not contract.
Moreover, these cells became bigger and flattened out. This change in appearance went hand in
hand with the cells becoming unable to divide and form new cells. However, cells that lacked just
one type of ROCK protein were still able to divide and proliferate.
As tumors form as a result of cells dividing and proliferating uncontrollably, Ku¨mper et al. then
studied how the ROCK proteins affect tumor development in mice that are susceptible to lung or
skin cancer. Although cancerous cells were found that contained just one type of ROCK protein, no
tumor cells were found that lacked both ROCK1 and ROCK2, further confirming that having one
ROCK protein is essential for tumor formation.
Overall, it appears that within the systems studied ROCK1 and ROCK2 perform the same roles,
and that ROCK proteins are indispensable for cell proliferation and hence tumor development. The
next challenge will be to identify the tumor types that are highly dependent on processes driven by
the ROCK proteins. Further work could then investigate whether drugs that inhibit the activity of the
ROCK proteins block the growth and spread of these tumors.
DOI: 10.7554/eLife.12203.002
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inserting LoxP sites flanking exon 6 in the Rock1 locus and exons 5 and 6 in the Rock2 locus (Fig-
ure 1—figure supplement 1A). These exons are located within the kinase domain and their deletion
results, through frameshifts, in the absence of ROCK proteins. We first generated cells lacking
ROCK1 (Rock1D/D), ROCK2 (Rock2D/D) or ROCK1 and 2 (Rock1D/D;Rock2D/D) by isolating mouse
embryo fibroblasts (MEFs) from embryos with the following genotypes: Rock1f/f;Rock2wt/wt, Rock1wt/
wt;Rock2f/f or Rock1f/f;Rock2f/f and infecting them with Adenovirus-expressing Cre recombinase (Ad-
Cre) or GFP (Ad-GFP). Depletion of ROCK1 and ROCK2 (Rock1D/D;Rock2D/D) resulted in a strong
impairment of cell proliferation in vitro, which was not observed in cells lacking either ROCK1
(Rock1D/D) or ROCK2 (Rock2D/D) (Figure 1A), demonstrating that ROCK function is required for cell
proliferation and that ROCK1 and ROCK2 act redundantly. Infection of cells with adenovirus is not
100% efficient, and when the growth of Rock1D/D;Rock2D/D cells was monitored over a longer period
of time, these cells eventually recovered their ability to proliferate (Figure 1—figure supplement
1B), but western blot analysis revealed that these cells express ROCK1 and 2 in equivalent levels to
wild type cells (data not shown) and thus likely originated from uninfected cells.
As genetic depletion abrogates ROCK function long term, we investigated whether long-term
treatment of cells with ROCK inhibitors caused proliferation defects. Cells treated for 48 hr with the
ROCK inhibitor H1152 (Sasaki et al., 2002) had reduced proliferation (Figure 1B). Similar results
were observed with other ROCK inhibitors, such as GSK269962A, AT13148, GSK429286A and chro-
man1 (data not shown). However, the much-used ROCK inhibitor Y-27632 (Narumiya et al., 2000)
had a much weaker effect on cell proliferation than H1152 (Figure 1—figure supplement 1C). This
is consistent with previous studies, where we have shown that Y-27632 is a less effective ROCK inhib-
itor than H1152 (Sadok et al., 2015). To determine whether defects in proliferation were due to
ROCK-mediated effects on actomyosin contractility, cells were treated with blebbistatin, an inhibitor
of myosin II ATPase, for 48 hr. Treated cells displayed a similar proliferation defect to that observed
in Rock1D/D;Rock2D/D cells (Figure 1B), arguing that the requirement for ROCK in cell proliferation is
mediated through its role in maintaining actomyosin contractility.
To test whether Rock1D/D, Rock2D/D orRock1D/D;Rock2D/D MEFs can proliferate in vivo, MEFs iso-
lated from Rock1f/f, Rock2f/f or Rock1f/f;Rock2f/fmice were immortalized with retrovirus expressing a
dominant-negative form of Trp53 (Trp53 DD) (Hahn et al., 2002), and subsequently transformed
with a retrovirus expressing mutant H-Ras (H-RasV12). The cells were then treated with Ad-Cre or
control virus and, 5 days later, injected subcutaneously and tumor growth monitored. No differences
in tumor growth were observed when transformed MEFs, derived from Rock1f/for Rock2f/f cells,
infected with Ad-Cre were compared to control virus (Figure 1C,D). In contrast, transformed
Rock1D/D;Rock2D/D MEFs grew significantly slower in vivo compared to controls (Figure 1E). Western
Blot analysis revealed the retention of ROCK1 and 2 protein in tumors derived from Rock1D/D;
Rock2D/D (Trp53 DD; H-RasV12) MEFs but complete deletion of ROCK1 in Rock1D/D and ROCK2 in
Rock2D/D tumor samples (Figure 1F, data not shown), in agreement with the observed results on
proliferation in vitro. This result shows that injected Rock1D/D;Rock2D/D cells are unable to proliferate
and form tumors but the un-infected cells can proliferate and form tumors thereby accounting for
the delay in tumorigenesis and implying that ROCK function is essential for proliferation and hence
tumor initiation and formation.
We here show that concomitant depletion of ROCK1 and ROCK2 leads to defects in cell prolifera-
tion in vitro as well as in vivo. Depletion of a single ROCK isoform however has no effect, suggesting
they can act redundantly.
ROCK1 and ROCK2 act redundantly to regulate actomyosin
contractility and cell shape
In order to identify causes for the defects in cell proliferation seen in cells lacking ROCK1 and
ROCK2 (Rock1D/D;Rock2D/D), we characterized their cell morphology. One of the most prominent
responses to activated ROCK is the generation of actin stress fibers, which regulate cell shape
(Amano et al., 1997; Ridley, 1999). A previous report using RNA interference suggested that
ROCK1, rather than ROCK2, is important for stress fiber formation (Yoneda et al., 2005). After thor-
ough analysis of ROCK depletion upon infection with Ad-Cre or Ad-GFP, a slight decrease in protein
levels was observed after three days (Figure 2—figure supplement 1A). After four days a further
reduction was seen and after five days both ROCK1 and 2 were depleted (Figure 2B–C). Three days
after infection with Ad-Cre, Rock1D/D;Rock2D/D cells lacked stress fibers and displayed a ‘tail
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Figure 1. Depletion of ROCK1 and 2 leads to defects in cell proliferation in vitro and in vivo. (A) Proliferation curves of MEFs with different genotypes
over 6 days. The cells were seeded 3 d after adenovirus infection. Graphs show total number of cells and SD from 5 independent experiments each
carried out in triplicates. p-values were calculated using Student’s t-test: ** p<0.005; *** p<0.001. (B) Rock1f/f;Rock2f/f control and Rock1D/D;Rock2D/D
MEFs were cultured for 3 days and wild-type cells were treated with H1152, inactive blebbistatin (+) or active blebbistatin (+/-) for 48 hr. Cells from all
conditions were then subjected to a colony formation assay and grown for a further 7 days. (C–F) Rock1f/f;Rock2f/f MEFs transformed with Trp53 DD and
HRas V12 were treated with Ad Cre to generate D. Cells were injected subcutaneously into CD1 nude mice and growth analyzed. The graph shows
average tumor volume in mm3 and SEM for Rock1D/D and control (C), Rock2D/D and control (D), Rock1D/D;Rock2D/D and control (E). p values were
calculated by ANOVA and are as indicated. (F) Tumors with stated genotypes were immunoblotted with indicated antibodies.
DOI: 10.7554/eLife.12203.003
The following figure supplement is available for figure 1:
Figure supplement 1. Generation of conditional Rock alleles and cell proliferation analyses.
DOI: 10.7554/eLife.12203.004
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retraction’ phenotype, a well-known characteristic of ROCK inhibition (Somlyo et al., 2000). Cells
had long processes and defects in detaching their tails, in contrast to their controls (Figure 2A and
Videos 1,2). A similar phenotype was observed in cells treated with the ROCK inhibitor H1152 or
the myosin II inhibitor blebbistatin but not in cells lacking either ROCK1 (Rock1D/D) or ROCK2
(Rock2D/D) (Figure 2A). After five days, cells that lack both ROCK1 and ROCK2 had few apparent
central stress fibers, unlike control cells, and surprisingly adopted a flat morphology (Figure 2A and
Videos 1,2). This phenotype seemed to appear gradually after prolonged loss of ROCK which was
seen three days after adenovirus infection. Interestingly, when random motility was analyzed
between Days 3 and 4 after adenovirus infection, using ImageJ to track cells, migration speed and
directionality were significantly increased in cells lacking ROCK1 and 2 (Figure 2—figure supple-
ment 1B). This was previously described by Lomakin et al. (Lomakin et al., 2015).
Consistent with the levels of stress fibers, phosphorylation of MYPT and MLC were only affected
in cells where both ROCKs had been removed (Figure 2B–C, quantification in Figure 2—figure sup-
plement 1C), showing that ROCK1 and ROCK2 act redundantly in regulating MYPT and MLC phos-
phorylation. While MYPT Thr850 phosphorylation was markedly reduced in Rock1D/D;Rock2D/D cells,
MYPT Thr696 phosphorylation was not (Figure 2B, quantification in Figure 2—figure supplement
1C), suggesting that, while Thr850 is principally regulated by ROCKs, Thr696 is regulated by other
kinases such as MRCK (Wilkinson et al., 2005). ROCK1 levels were slightly but not significantly
increased in Rock2D/D cells and vice versa (Figure 2—figure supplement 1C).
Rock1D/D;Rock2D/D MEFs spread when plated on a thick layer of collagen 5 days after adenovirus
infection, unlike Rock1D/D or Rock2D/D cells which had a more spindle-like morphology similar to
wild-type controls (Figure 2D). This indicates reduced cellular contractility upon loss of ROCK1 and
2. As a functional measure of actomyosin contractility, we used a gel contraction assay
(Hooper et al., 2010), demonstrating that cells containing only ROCK1 or ROCK2 were able to con-
tract a collagen gel, but cells lacking both ROCK1 and ROCK2 were not (Figure 2E), supporting the
notion ROCK1 and ROCK2 act redundantly to maintain cellular contractility.
To further investigate ROCK signaling, we analyzed the temporal profile of changes in the phos-
pho-proteome upon ROCK inhibition using mass spectrometry. Short-term inhibition of ROCK, using
H1152, resulted in a significant decrease in phosphorylation of many phospho-sites, including several
known targets of ROCK such as Cofilin-1 (Ser-3), Cofilin-2 (Ser-3), Destrin (Ser-3), and Ser-19/Thr-20
of MLC (Supplementary file 1 and Figure 2—figure supplement 1D). However, the majority of
these phosphorylation sites, with the exception of MLC Ser-19/Thr-20, were only transiently affected,
as their phosphorylation was fully recovered in long-term ROCK inhibited cells (Supplementary file
1 and Figure 2—figure supplement 1E) or Rock1D/D;Rock2D/D cells (Figure 2B–C). These results
indicate that alternative phosphorylation mechanisms exist for some ROCK substrates, but that no
other kinase previously implicated in MLC phosphorylation can substitute for ROCK1/2 in the gener-
ation of actomyosin contractility.
In summary, we showed that short-term (three days after Ad-Cre infection) depletion of ROCKs
induces a previously described ‘tail retraction’ phenotype but surprisingly long-term (from five days
after Ad-Cre infection) depletion induces a further change in morphology resulting in a flattened
morphology and decrease in central stress fibers.
Loss of ROCK-dependent actomyosin contractility leads to cellular
senescence
The flattened and enlarged morphology observed upon long-term depletion of ROCK1 and ROCK2
is typical of cellular senescence. Indeed, Rock1D/D;Rock2D/D MEFs, or MEFs treated with H1152 or
blebbistatin for prolonged periods exhibited a significant increase in staining for senescence-associ-
ated b-galactosidase (SA-bGal) (Debacq-Chainiaux et al., 2009) than control cells (Figure 3A).
Senescence was also observed after prolonged treatment with other ROCK inhibitors such as
GSK269962A, AT13148, GSK429286A and chroman1 (Figure 3—figure supplement 1A). To deter-
mine whether abrogation of ROCK function causes senescence in vivo, we used the recently
described inhibitor AT13148 that has been shown to potently inhibit ROCK and has been previously
used in vivo (Sadok et al., 2015; Yap et al., 2012a). 690cl2 mouse melanoma cells were injected
intra-dermally into CD1 athymic mice, and the mice treated with AT13148 at 40 mg/kg. Senescence
was detected by SA-bGal staining of tumors. We observed a decrease in tumor growth when mice
were treated with AT13148 compared to controls (Figure 3—figure supplement 1B). Additionally,
Ku¨mper et al. eLife 2016;5:e12203. DOI: 10.7554/eLife.12203 5 of 24
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Figure 2. Only deletion of both ROCK1 and 2 leads to a loss of central stress fibers and a decrease in actomyosin
contractility. (A) Images of wild-type, Rock1D/D, Rock2D/Dor Rock1D/D;Rock2D/D MEFs, 3 days after Ad-GFP and Ad-
Cre-GFP infection, stained for pMLC and phalloidin. Wild-type and Rock1D/D;Rock2D/D cells are also shown 5 days
after Ad-GFP and Ad-Cre-GFP infection. Scale bars are 50 mm. (B, C) Western blot analyses of ROCK targets in
lysates of MEFs with indicated genotypes. Representative blots are shown, quantification of multiple biological
replicates can be found in Figure 2—figure supplement 1C. (D) Images of MEFs with indicated genotypes plated
on a thick layer of collagen and stained for phalloidin. Scale bars are 50 mm. (E) Images and quantification of
collagen gel contraction assay using MEFs of indicated genotypes. Graph shows average data and SD from 5
independent experiments, each carried out in triplicate. p-values were calculated using Student’s t-test:
***p<0.001.
DOI: 10.7554/eLife.12203.005
Figure 2 continued on next page
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we observed an increase in the number of SA-bGal positive cells within tumors (Figure 3—figure
supplement 1C).
Analysis of Rock1D/D;Rock2D/D cells by microscopy revealed a significant increase in the number of
cells with two nuclei (Figure 3B), indicating a failure of cytokinesis. During cytokinesis an actomyo-
sin-based contractile ring is formed to drive cleavage furrow ingression, which subsequently results
in two daughter cells. ROCK and the related Citron kinase have been shown to localize to the cleav-
age furrow, yet it is not entirely clear which kinase regulates MLC phosphorylation at the furrow to
generate actomyosin contractility (Kosako et al., 1999; 2000; Madaule et al., 1998). Analysis of
time-lapse movies further confirmed a role for ROCK1 and 2 in cytokinesis as a greater percentage
of Rock1D/D;Rock2D/D cells failed to divide compare to wild-type cells (Figure 3C and Videos 3,4). In
addition to an increased number of binucleate cells, analysis of time-lapse movies of Rock1D/D;
Rock2D/D cells revealed an overall lower number of dividing cells (Figure 3D and Videos 3,4). These
data suggest that cells depleted of ROCK1 and 2 do not initiate division further, thus indicating a
cell cycle block.
To analyze the cell cycle profile of Rock1D/D;Rock2D/D cells, cells were stained with propidium
iodide (PI) along with control cells for analysis by flow cytometry. Fewer double knockout than wild-
type MEFs were in G1 or S phase, and a higher percentage of cells in G2/M phase of the cell cycle
(Figure 3E). The increased percentage may be due to the fact that binucleate cells in G1 will have
the same DNA content as cells in G2/M. To investigate a potential cell cycle block, we treated
Rock1D/D;Rock2D/D cells and their controls with nocodazole, commonly used to arrest cells with a G2/
M phase DNA content (Blajeski et al., 2002). In controls, nocodazole led to an increased proportion
of cells with G2/M DNA content as expected (Figure 3—figure supplement 1D). In Rock1D/D;
Rock2D/D cells, however, distribution of cells in the three cell cycle phases is very similar between
control treated and nocodazole treated cells (Figure 3—figure supplement 1D). These data sug-
gest that ROCK depletion causes a cell cycle block prior to G2/M. As there is an overall decrease in
S phase cells, the block is likely to be in the G1 phase of the cell cycle.
ROCK regulates cell cycle proteins CKS1 and CDK1
We have shown that ROCK depletion or inhibition induces cellular senescence; therefore, we next
investigated whether they affected key cell cycle proteins involved in senescence. Two major path-
ways are activated by senescence signals. Activation of the transcription factor Trp53 induces
expression of p21, a cyclin-dependent kinase inhibitor (CDKI) (Brown et al., 1997). The other path-
way is induction of the CDKI p16, which prevents CDK4/6-mediated phosphorylation of
Figure 2 continued
The following figure supplement is available for figure 2:
Figure supplement 1. Depletion of ROCK leads to an increase in migration speed and persistent down-regulation
of Myosin Regulatory Light Chain (Mrlc) phosphorylation.
DOI: 10.7554/eLife.12203.006
Video 1. Rock1f/f;Rock2f/f control, 3 days after infection
with Ad-GFP, 10X magnification.
DOI: 10.7554/eLife.12203.007
Video 2. Rock1D/D;Rock2D/D, 3 days after infection with
Ad-Cre, 10X magnification.
DOI: 10.7554/eLife.12203.008
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Figure 3. Rock1D/D;Rock2D/D cells undergo senescence and show a cell cycle block. (A) Images of MEFs treated with H1152, blebbistatin (+),
blebbistatin (+/-) for 5 days and Rock1f/f;Rock2f/f control, Rock1D/D;Rock2D/D MEFs, 5 days after Ad-GFP and Ad-Cre-GFP infection and followed by SA-b
gal staining. Scale bars are 50 mm. Graph shows number of SA-bgal expressing cells divided by total number of cells and SD of >100 cells from three
independent experiments and p-values were calculated using Student’s t-test: *** p<0.001. (B) Images of Rock1f/f;Rock2f/f and Rock1D/D;Rock2D/D MEFs
stained with phalloidin and DAPI. Overlay images shown. Arrows in image indicate binucleate cells. Scale bars are 50 mm. Bar chart shows average data
and SD of nuclei in > 150 cells from 5 independent experiments. Values were calculated using Student’s t-test: * p<0.05. (C, D) Analysis of cell division
of Rock1f/f;Rock2f/f and Rock1D/D;Rock2D/D MEFs in time-lapse movies. (C) Quantification of failed cell divisions resulting in binucleate cells. (D)
Quantification of average number of cells dividing. Graphs show average data and SD of > 300 cells from at least five independent experiments. (E)
Cell cycle profiles of Rock1f/f;Rock2f/f and Rock1D/D;Rock2D/D MEFs. The graph shows the percentage of cells in G2/M (top), S (middle) and G1 (bottom)
phase of the cell cycle. Error bars represent SD. Data are from 5 independent experiments and p-values were calculated using Student’s t-test: *
p<0.05.
DOI: 10.7554/eLife.12203.009
Figure 3 continued on next page
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retinoblastoma (Rb) proteins, thereby blocking E2F-dependent transcription (Brenner et al., 1998;
Nevins, 2001). To determine whether blockade of Rb or Trp53 function would overcome senes-
cence resulting from abrogation of ROCK function, we stably infected Rock1f/f;Rock2f/fMEFs with
simian virus 40 large T-antigen (SV40 Large T), which is known to inactivate the tumor suppressors
Trp53 and Rb (DeCaprio et al., 1988; Kierstead and Tevethia, 1993). The cells were then infected
with Ad-Cre, to generate Rock1D/D;Rock2D/D cells (Figure 4—figure supplement 1A). Inactivation of
Trp53 and Rb did not prevent the senescence phenotype caused by loss of ROCK, and cells dis-
played a similar growth defect to the one observed in Rock1D/D;Rock2D/D MEFs without SV40 Large
T (Figure 4—figure supplement 1A). To further confirm that the senescent phenotype did not
involve activation of Trp53, MEFs were isolated from Rock1f/f;Rock2f/f;Trp53f/f mice and ROCK and
Trp53 depleted in vitro by Ad-Cre infection. Rock1D/D;Rock2D/D;Trp53D/D MEFs were found to
undergo senescence, and were defective in their proliferation (Figure 4—figure supplement 1B).
Western blot analysis confirmed depletion of both ROCKs and Trp53 (Figure 4—figure supplement
1B). We then treated Trp53 wild type and null cells with the ROCK inhibitors H1152 and
GSK269962A and found an increase in senescence compared to control cells (Figure 4—figure sup-
plement 1C). Therefore, the classical senescence pathways did not seem to be affected in Rock1D/D;
Rock2D/D cells or cells treated for prolonged periods with H1152. To identify protein changes associ-
ated with senescence, we used immunoblotting and quantitative mass spectrometry (Ong et al.,
2002). The protein levels of some cell cycle regulators appeared to change upon treatment with Cre
recombinase alone, so for proteomics analysis we focused on long-term H1152 treatment. Annota-
tion enrichment analysis (Cox and Mann, 2008) of the proteome-wide changes after long-term
ROCK inhibition revealed many cell cycle-related protein categories that were significantly modu-
lated in ROCK-inhibited cells (Supplementary file 2), consistent with a prominent cell-cycle pheno-
type. However, when we analyzed proteins that are known to control G1 cell-cycle arrest and
senescence, we did not detect significant changes in the levels of these proteins. These included
known regulators, such as p16, p19, p27, p21, CyclinD1, CyclinE, or phosphorylation of Rb
(Supplementary file 2 and Figure 4—figure supplement 2A,B). However, CDK1, CyclinA and CKS1
protein levels were significantly reduced upon loss of and long-term inhibition of ROCK1 and 2
(Supplementary file 2 and Figure 4A–C). Long-term treatment of cells with blebbistatin (blebbista-
tin +/-), but not the inactive enantiomer (blebbistatin +), also decreased the levels of CDK1, CyclinA
and CKS1 (Figure 4B,C), suggesting that it is loss of contractility downstream of ROCK loss that
results in down-regulation of these proteins. However, it cannot be ruled out that both ROCK inhibi-
tion/depletion as well as myosin II inhibition independently lead to a similar phenotype.
Cyclin-dependent kinase regulatory subunits 1 and 2 (Cks1b and Cks2) form a complex with a
subset of cyclin-dependent kinases (Cdks) that are the essential regulators of cell cycle progression.
Mammalian cells in which Cks is silenced exhibit a slowed G1 progression and arrest in G2/M phase
of the cell cycle, and are therefore unable to enter mitosis (Martinsson-Ahlzen et al., 2008;
Westbrook et al., 2007). It was previously reported that siRNA knockdown of CKS1 protein in
Cks2-/-Cks1b+/- MEFs leads to a decrease in proliferation through defects in Cdk1, Ccna2 and Ccnb1
transcription and expression of the equivalent proteins CDK1, CyclinA and CyclinB (Martinsson-
Ahlzen et al., 2008). Analysis of mRNA levels revealed that, in Rock1D/D/Rock2D/D cells, Cdk1 and
Ccna2 mRNA levels were significantly reduced, whereas Cks1b mRNA remained unchanged
(Figure 4D). APC/CCdh1 (anaphase-promoting complex and its activator Cdh1) have been previously
implicated in regulating CKS1 as well as SKP2 stability (Bashir et al., 2004). We were unable to
detect SKP2 protein in the cells, but CKS1 protein was still downregulated when Cdh1 null MEFs
were treated with H1152 or blebbistatin (data not shown). Furthermore, MG132 treatment of cells
did not prevent downregulation of CKS1 suggesting the proteasome is not responsible for this
decrease (data not shown).
To determine whether the down-regulated cell cycle regulators are responsible for the phenotype
induced by the loss of ROCK 1 and 2, we employed shRNA knockdown of Cks1b, Cdk1 and Ccna2.
Figure 3 continued
The following figure supplement is available for figure 3:
Figure supplement 1. Analysis of senescence in ROCK-inhibited cells and induction of a cell cycle block in ROCK-depleted cells.
DOI: 10.7554/eLife.12203.010
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Cells depleted of CKS1, CDK1 or CyclinA were unable to proliferate (Figure 5A) and had increased
staining for SA-bGal (Figure 5B). Interestingly, it has been shown previously that the knockout of
Cks1b (Hoellein et al., 2012) or Cdk1 (Diril et al., 2012) leads to cellular senescence. We found that
knockdown of Cks1b affected protein levels of CDK1 and CyclinA, while knockdown of Cdk1
affected protein levels of CKS1 and CyclinA and knockdown of Ccna2 affected levels of CKS1 and
CDK1 (Figure 5C), confirming a clear link between the expression of these proteins. Overall, these
results indicate that cell cycle proteins CKS1, CDK1 and CyclinA are downregulated upon loss of
actomyosin contractility, and their depletion causes defects in cell proliferation and increased cellular
senescence.
ROCK function is essential for tumorigenesis, but ROCK1 and 2
proteins act redundantly
After thorough in vitro characterization of cells lacking ROCK1 and ROCK2, we investigated the roles
of ROCK1 and ROCK2 in tumorigenesis in vivo using genetically engineered mouse tumor models.
To this end, we interbred mice carrying the conditional Rock alleles with models of lung tumorigene-
sis and melanoma. Activation of the LSL-oncogenes KrasG12D and BrafV600E in these models by Cre
recombinase also leads to deletion of conditional Rock alleles.
For lung tumorigenesis, we used a NSCLC model, exploiting activation of LSL-KrasG12Dand LSL-
Trp53R270H in lung epithelial cells (DuPage et al., 2009; Jackson et al., 2005; 2001). Mice were
treated with adenovirus expressing Cre (Ad-Cre) and sacrificed 24 weeks after treatment. Histologi-
cal analysis revealed that the total tumor area was increased in Rock1f/f mice (Figure 6A). This was
seen for all tumor grades (Figure 6A) that have been classified as reported previously
(DuPage et al., 2009; Jackson et al., 2005; 2001). This result suggests that ROCK1 may have a
tumor suppressor function in this specific mouse model, of which the mechanism requires further
investigation and will be the subject of another manuscript. However, no difference was seen com-
paring tumor area of Rock1f/f;Rock2f/f or Rock2f/f with wild type mice (Figure 6A). Western blot anal-
ysis of cell lines generated from Rock1f/f;Rock2f/f;KrasG12D; Trp53R270H-driven tumors showed that
they always retained ROCK1 or ROCK2 protein (Figure 6B) and contained un-recombined floxed
alleles of Rock1 and 2. To investigate the consequences of complete loss of ROCK function, we
infected these ‘retainer’ cell lines isolated from lung tumors arising in Rock1f/f;Rock2f/f mice, which
retained ROCK1 protein (Rock1f/f;Rock2D/D), with Ad-Cre-GFP to excise the retained Rock1 locus.
The same procedure was applied to cells isolated from tumors arising in Rock1f/wt;Rock2f/f mice
(Rock1D/wt;Rock2D/D). Rock1D/D;Rock2D/D cells, but not Rock1D/wt;Rock2D/D cells, failed to proliferate
when compared to the control cells in a colony formation assay (Figure 6C). This further highlights
the fact that one wild-type allele of Rock is sufficient to allow cell proliferation. Importantly, we find
that just one allele of either Rock is sufficient to rescue the proliferation defect which was also
observed using MEFs (data not shown) and this Rock1D/wt;Rock2D/D cell line (Figure 6C).
In order to quantify ROCK1 and ROCK2 protein abundance from each knockout, we established
a custom-selected reaction monitoring (SRM) targeted mass-spectrometry assay (Worboys et al.,
2014). This enables the analysis of absolute concentrations of each isoform, allowing us to identify
Video 3. Rock1f/f;Rock2f/f control, 5 days after infection
with Ad-GFP, 20X magnification.
DOI: 10.7554/eLife.12203.011
Video 4. Rock1D/D;Rock2D/D, 5 days after infection with
Ad-Cre, 20X magnification.
DOI: 10.7554/eLife.12203.012
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Figure 4. Downregulation of CKS1, CyclinA and CDK1 on abrogation of ROCK function. (A) MEFs were treated with H1152 or vehicle for 3 days and the
proteome analyzed by quantitative mass spectrometry. Graph shows log ratios of identified proteins. Data are from duplicate experiments of reciprocal
SILAC labelling. The ‘Significant-B’ outlier test was used to determine significantly regulated peptides or proteins, using a Benjamini-Hochberg FDR
rate of 5%. (B, C) MEFs of different genotypes or treated with indicated inhibitors were immunoblotted for pCDK1, total CDK1, Cyclin A, CKS1, ROCK1,
ROCK2 and total ERK as loading control (B). (C) Quantification of western blot analyses. Graphs show protein levels of CDK1, CyclinA and CKS1 divided
by total ERK protein levels and SEM in indicated samples. The data are from 5 independent experiments and p-values were calculated using Student’s
t-test: * p<0.05, ** p<0.005, *** p<0.001. (D) qPCR analysis of mRNA levels of Cks1b, Cdk1 and Ccna2 in indicated samples. Graphs show average
normalized mRNA levels and SD from at least five independent experiments, each carried out in triplicates. p-values were calculated using Student’s t-
test: * p<0.05, *** p<0.001.
DOI: 10.7554/eLife.12203.013
Figure 4 continued on next page
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whether one isoform is more expressed than the other and thus could play a more important role. It
will also allow analysis of whether loss of one isoform would lead to a compensatory increase in
the levels of the other isoform. Isotopically ‘heavy’ synthetic quantotypic ROCK1 and ROCK peptides
were correlated with ROCK1 and ROCK2 to calculate absolute protein abundance from each sam-
ple. SRM analysis showed that, in cell lines derived from tumors in Rock1f/f;Rock2f/fmice, either
ROCK1 or ROCK2 protein was always retained (Figure 6D). ROCK1 and ROCK2 protein was absent
in cell lines derived from Rock1f/f or Rock2f/ftumor bearing mice, respectively (Figure 6D). Micro-
Figure 4 continued
The following figure supplements are available for figure 4:
Figure supplement 1. Analysis of cellular senescence in Rock1D/D;Rock2D/D;Trp53D/D cells and in ROCK-inhibited Trp53 wild type and Trp53 null cells.
DOI: 10.7554/eLife.12203.014
Figure supplement 2. Protein levels of cell cycle regulators in ROCK-inhibited and Rock1D/D;Rock2D/D cells.
DOI: 10.7554/eLife.12203.015
Figure 5. Knockdown of Cdk1 and Cks1b leads to cellular senescence. (A–C) MEFs were infected with either control shRNA or shRNAs targeting Cks1b,
Cdk1 and Ccna2. Four days after infection, equal numbers of cells were plated and kept for seven days, allowing colonies to form (A). Five days after
infection with shRNAs, cells were also subjected to SA-bGal staining (B) and immunoblotting with antibodies against pCDK1, total CDK1, Cyclin A,
CKS1. ROCK2 and total ERK were used as loading control (C). Scale bars are 50 mm.
DOI: 10.7554/eLife.12203.016
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Figure 6. ROCK is essential for tumorigenesis. Cohorts of mice carrying LSL-KrasG12D; LSL-Trp53R270H alleles and the indicated Rock alleles were
treated once with Ad-Cre viruses by intranasal inhalation. 24 weeks later, the mice were sacrificed and the lungs were analyzed by histopathology. (A)
Graphs show tumor area divided by lung area for indicated genotypes and tumor grades. The data are also displayed as a sum of tumor area divided
by lung area for the indicated genotypes. Graphs show average data and SEM. The total number of mice analyzed is indicated in Scatter Plots. (B) Cell
lines derived from KrasG12D;Trp53R270H tumors of either Rock1f/f, Rock2f/f, Rock1f/f;Rock2f/f or wild-type genotype were subjected to immunoblotting
with indicated antibodies. (C) Isolated lung tumor cell lines of Rock1D/wt;Rock2D/D genotype as well as a cell line which retained both Rock1 alleles
(Rock1f/f;Rock2D/D) were treated with Ad-GFP and Ad-Cre-GFP. 3 days after infection, cells were plated and kept for ~5 days allowing colonies to form.
(D) Absolute quantification of ROCK1 and 2, using selective reaction monitoring (SRM). Bar graphs show the mean concentration in nM of ROCK1
(black) and ROCK2 (grey) across at least 3 biological replicates from each genetic background. Line 1–3 indicate different cell lines isolated from
NSCLCs and Tumors 1–4 represent different micro-dissected tumors. Error bars represent SEM.
DOI: 10.7554/eLife.12203.017
The following figure supplement is available for figure 6:
Figure supplement 1. Analysis of melanomagenesis in wt, Rock1f/f, Rock2f/f and Rock1f/f;Rock2f/f mice.
DOI: 10.7554/eLife.12203.018
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dissected tumors from Rock1f/f mice showed a reduction of ROCK1 protein levels but not complete
depletion as seen in cell lines. This is likely due to contamination from the wild type stromal cells
infiltrating the tumor. The same was also observed in tumors from Rock2f/f mice (Figure 6D). In
tumors analyzed from Rock1f/f;Rock2f/fmice, ROCK2 protein was retained but low levels of ROCK1
were also present (Figure 6D), most probably from stromal cells. Importantly, ROCK1 protein was
not up-regulated in cell lines or tumors from mice with Rock2f/f genotype in a compensatory manner
and vice versa. The overall concentration of ROCK1 and 2 proteins was found to be similar, exclud-
ing potential effects driven by differential isoform expression.
Similar results were also observed in mouse models of melanoma (Dhomen et al., 2009). In the
melanoma model, expression of BrafV600E from an LSL-BrafV600E allele is driven in melanocytes by a
tamoxifen-activated version of Cre recombinase under the control of the melanocyte-specific tyrosi-
nase promoter (Tyr-CreERT2) (Dhomen et al., 2009). We also used conditional melanocyte-specific
expression of oncogenic Braf in combination with a conditional allele of the Pten tumor suppressor
to decrease tumor latency (Dankort et al., 2009; Dhomen et al., 2009) (Figure 6—figure supple-
ment 1A–B). No differences were found in onset of tumorigenesis (Figure 6—figure supplement
1A) or survival (Figure 6—figure supplement 1B) when comparing BrafV600E with BrafV600E;Rock1f/f
or BrafV600E;Rock1f/f;Rock2f/f mice. Tumor latency was decreased in BrafV600E;Rock2f/fmice only but
not in combination with Ptenf/f or Ptenf/wt (Figure 6—figure supplement 1A). Survival was also
found to be decreased in BrafV600E:Rock2f/fmice as well as in combination with Ptenf/f (Figure 6—fig-
ure supplement 1B), suggesting that unlike in the NSCLC model, ROCK2 may be having a tumor
suppressor role in this model.
Nevertheless, similar to the NSCLC model, analysis of cell lines generated from these melanomas,
by SRM and immunoblotting, revealed retention of either ROCK protein in mice with Rock1f/f;
Rock2f/fgenotype, but efficient excision of the floxed locus in mice with Rock1f/f and Rock2f/f geno-
types (Figure 6—figure supplement 1C–D). These results further support our observation that
ROCK protein is required for tumorigenesis, since retention of at least one Rock allele is selected for
in both Ras-driven lung tumors and Raf-driven melanomas. Furthermore, treatment of melanoma cell
lines with Ad-Cre-GFP, to excise the retained Rock locus, revealed that Rock1D/D;Rock2D/D cells but
not Rock2D/D cells fail to proliferate compared to control cells in a colony formation assay (Figure 6—
figure supplement 1E). This was also seen when compared to Rock1D/D cells (data not shown).
Collectively, analysis of ROCK1 and ROCK2 protein expression in tumors and tumor derived cell
lines suggests that the absence of ROCK1 and ROCK2 is incompatible with tumorigenesis. However,
either ROCK1 or ROCK2 protein is sufficient to promote tumorigenesis.
Discussion
Rho-kinase generates actomyosin contractility and thus has been described as an important regula-
tor of cell motility and plasticity (Sanz-Moreno et al., 2008). Several reports using siRNA to knock-
down ROCK1 or 2 have been published suggesting that ROCK1 and 2 proteins are not redundant.
These include different effects on actomyosin contractility, stress fibers and focal adhesions in fibro-
blasts (Yoneda et al., 2005), opposing effects on cell proliferation and changes in cell migration in
glioblastoma cell lines (Mertsch and Thanos, 2014). Using ROCK1 and 2 single knockout MEFs, dif-
ferences in stress fiber formation and Cofilin phosphorylation have been described (Shi et al., 2013).
In a further study, knockdown of either ROCK1 or ROCK2 alone was sufficient to reduce anchorage-
independent growth of NSCLC cell lines - also suggesting their functions are not redundant
(Vigil et al., 2012). All of these studies, however, describe very different effects of ROCK1 or
ROCK2, and at least partially contradict each other. The use of siRNA knockdown, ROCK inhibitors
or germ-line knockout MEF lines has several limitations, such as off-target effects, differences in
growth properties or cell morphology. To establish an isogenic system and to circumvent the sever-
ity of the embryonic phenotypes in germ-line knockouts of Rock1 and 2 (Shimizu et al., 2005;
Thumkeo et al., 2003; Thumkeo et al., 2005), we generated conditional targeted alleles of Rock1
and Rock2, allowing us to analyze of the role of ROCK1 and ROCK2, and permitting the generation
of cells that lack both ROCK1 and 2. Our data with genetic deletion in an isogenic fashion show that
either ROCK1 or ROCK2 is sufficient to regulate MLC and MYPT phosphorylation and thus actomyo-
sin contractility. Known targets such as the phosphorylation of cofilin are not affected in single or
double knockout cells. However, using quantitative mass spectrometry treatment of cells with the
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ROCK inhibitor H1152, we show that Cofilin phosphorylation is affected after short-term ROCK inhi-
bition but recovers upon long-term treatment. This indicates that other kinases are able to take over
and phosphorylate Cofilin. MLC phosphorylation, however, is not recovered indicating that ROCK is
the major kinase regulating MLC phosphorylation.
We demonstrate that the depletion of ROCK1 and 2 leads to severe defects in cell proliferation,
which is not observed in cells lacking either ROCK1 or 2. Defects in cell proliferation are also
observed in cells treated long-term with ROCK inhibitors or the MyosinII inhibitor blebbistatin. Previ-
ous work with the ROCK inhibitor Y-27632 has led to contradictory results on the requirement for
ROCK in cell proliferation. We believe that this may reflect the relatively low potency of Y-27632 as a
ROCK inhibitor, since we found that treatment with several other ROCK inhibitors (H1152,
GSK269962A, AT13148, GSK429286A and chroman1), which have been shown to be more potent
than Y-27632 (Sadok et al., 2015), could mimic the effects of genetic deletion of Rock1 and Rock2.
Cell proliferation defects upon deletion of ROCK1 and 2 are due to a G1 arrest and a block in
cytokinesis. Interestingly, the cell proliferation defects arising from abrogation of ROCK function
result in cellular senescence, both in vitro and in vivo. This cellular senescence does not appear to
involve changes in levels of the cell cycle inhibitors p16, p21, p27, but the down-regulation of cell-
cycle proteins CDK1, Cyclin A and the cyclin-dependent kinase inhibitor CKS1. CKS1 is known to
regulate levels of CDK1 and Cyclin A (Martinsson-Ahlzen et al., 2008; Westbrook et al., 2007),
and can function in G1 and G2 phases of the cell cycle (Tang and Reed, 1993). Interestingly, it has
been shown that Cks1b-/- cells are defective in proliferation, have reduced proportions of cells in S-
and G1-phase, accumulation of cells with G2/M DNA content (Hoellein et al., 2012; Spruck et al.,
2001) and exhibit senescence. We therefore propose that an essential function of ROCK in cell pro-
liferation is to regulate the expression of CKS1. In addition, this ROCK-driven CKS1 down-regulation
is a novel marker of senescence.
CKS1 does not appear to be regulated at the mRNA level, thus further studies are required to
understand how ROCK function could regulate CKS1 protein. Protein degradation was not mediated
by the proteasome or APC/CCdh1 complex (data not shown). APC/CCdh1 was previously shown to
regulate the degradation of CKS1 and Skp2 (Bashir et al., 2004). CKS1 and Skp2 are the targeting
subunits of the SCFSkp2–Cks1 ubiquitin ligase regulating p21 and p27 degradation (Sutterluty et al.,
1999). Even though we were unable to detect Skp2 in our system, we do show that p21 and p27 lev-
els are not affected upon loss of ROCK, suggesting a novel regulation of CKS1 and function in medi-
ating senescence. More work is required to unravel the complete mechanism and determine how
downregulation of these proteins is mediated.
We observed that treatment with blebbistatin a direct inhibitor of myosin II led to cell cycle arrest,
senescence and reduced levels of CKS1, CyclinA and CDK1, potentially suggesting that ROCK-
dependent regulation of cell proliferation is through the inhibition of actomyosin contractility rather
than another target of ROCK signaling.
Using tumor samples as well as tumor derived cell lines, from two different genetically engineered
mouse models of tumorigenesis, we find that tumor formation is incompatible with homozygous
deletion of both Rock1 and Rock2, since tumors arising in Rock1f/f;Rock2f/f mice always retained
either un-recombined Rock1f/for Rock2f/f alleles and showed expression of either ROCK1 or ROCK2,
respectively. Targeting either Rock1 or Rock2 appears to have mild and divergent consequences in
the mouse models. Deletion of Rock1 appears to increase tumor burden in the NSCLC model,
whereas deletion of Rock2 leads to decreased tumor onset and survival in the melanoma model.
These putative tumor suppressor functions of Rock1 and Rock2 do not appear to be a consequence
of differential expression as the absolute concentration of the two isoforms was found to be similar
by SRM. These results require further investigation and will be the basis of a separate manuscript.
The retention of ROCK protein in Rock1f/f;Rock2f/f mice, however, demonstrates that ROCK func-
tion is essential for tumorigenesis. Incomplete excision of proteins that affect cell proliferation has
been reported in several studies (Kissil et al., 2007; Peschard et al., 2012). In the tumor models
used in this study, excision of Rock alleles and tumor initiation are achieved simultaneously in an
inducible fashion; therefore we propose that the activation of Cre recombinase leads to the forma-
tion of a mixed population of cells in which either Rock, or both Rock1 and 2, have been excised.
The ROCK1 and 2 double-null cells, however, are unable to form a tumor as they are defective in
cell proliferation and senesce. The remaining cells, that is those that have retained either Rock allele
form tumors but these are the genetic equivalent of a single knockout.
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In summation, our data reveal that ROCK proteins act redundantly to regulate actomyosin con-
tractility, and that this function of ROCK is necessary, by supporting levels of the cell cycle regulators
Cyclin A, CDK1 and CKS1, for senescence, cell cycle progression and proliferation both in vitro and
in vivo. Recent studies have identified a role for ROCK inhibition in combinatorial treatments in
BRAF-mutant melanoma (Smit et al., 2014), as well as in Kras-driven lung cancers (Kumar et al.,
2012). Our data thus provide a molecular basis, and highlight the need, for exploiting the use of
effective ROCK inhibitors as anti-cancer agents either alone or in combination. However, incomplete
or specific inhibition of only one isoform of ROCK alone may not be an effective treatment, and may
even lead to adverse results as our results also highlight isoform specific tumor suppressive functions
for ROCK1 in lung and ROCK2 in melanoma models.
Materials and methods
Mice
All animal procedures were approved by the Animal Ethics Committee of the Institute of Cancer
Research in accordance with National Home Office regulations under the Animals (Scientific Proce-
dures) Act 1986. Rock1 and 2 gene-targeting vectors were made by inserting arms of homology into
the PGKneoF2L2DTA vector (Phillipe Soriano, Addgene plasmid #13445 [Hoch and Soriano, 2006]),
where loxP sites flank exon 6 of Rock1 (Rock1f/f) and exons 5–6 of Rock2 (Rock2f/f). Homologous
recombination was performed in Bruce4 ES cells of C57BL/6J origin (Ozgene). Positive clones were
identified by PCR and confirmed by Southern blotting before injection into albino C57BL/6J blasto-
cysts to generate chimeras in a pure C57BL/6J background. Rock1- and 2-targeted mice were subse-
quently crossed to PGK-Flp transgenic mice (provided by the Cancer Research UK transgenic facility)
to generate conditional knockout mice.
For the lung tumor model Rock1 and 2 targeted mice were crossed to LSL-KrasG12D (the mice
were a generous gift from David Tuveson [Tuveson et al., 2004]) and Trp53R270H. Mice were anes-
thetized and treated once by intranasal inhalation using 2106 pfu/mouse of Adeno-Cre viruses as
described previously (DuPage et al., 2009). Tumor grading is according to the Jacks’ lab classifica-
tion; AAD: Atypical Adenomatous Dysplasia not forming any solid elements; G1: Uniform small
rounded nuclei; G2: Enlarged nuclei with some variation and hyperchromatism, small nucleoli; G3:
Markedly enlarged and variable nuclei, prominent nucleoli, occasional mitotic figures; G4: Pleomor-
phic nuclei, prominent nucleoli, mitotic figures easily found, focal necrosis.
For the melanoma model, Rock1 and 2 targeted mice were crossed to mice carrying the trans-
genes LSL-BrafV600E, Ptenf/f (Ptenf/wt , Ptenwt/wt) and Tyr-CreERT2(the mice were a generous gift from
Richard Marais). Briefly, two treatment regimens were used; mice carrying Ptenf/wt and Ptenwt/wt tar-
geted alleles were treated with 100 ml of amoxifen (100 mg/ml in ethanol), tamoxifen was applied
evenly, to the shaven skin on the dorsal surface of 8-week-old mice. Mice carrying Ptenf/f targeted
alleles were treated with 0.5 ml of 4-Hydroxytamoxifen (4-OHT) (10 mM in DMSO); 4-OHT was
applied to shaven skin on the dorsal surface of 6-week-old mice three times on three consecutive
days.
Cell culture, reagents and treatments
MEFs were isolated from E13.5 embryos and cultured in a low-oxygen (3%) incubator
(Parrinello et al., 2003) in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum.
Tumors from mouse models were incubated in trypsin and put into culture to allow cells to grow
out. Melanomas were incubated at 20% oxygen for fibroblasts present in the culture to undergo
senescence and melanoma cells to grow out. All cell lines were subsequently analyzed by PCR and
immunoblotting and their genotypes confirmed. 690cl2 cells were generated in-house by N. Dho-
men and R. Marais from tumors arising in the BrafV600E, Ptenf/fmouse model (Dhomen et al., 2009).
Trp53 MEFs were generated in-house from the Trp53 knockout mouse (Harvey et al., 1993) and
their genotype confirmed by PCR.
All cell lines used for this study were generated in house and tested free of mycoplasma. Adeno-
viruses were obtained from the Gene Transfer Vector Core at the University of Iowa. SMARTchoice
lentiviral shRNA vectors were obtained from Dharmacon and produced in 293T cells co-transfected
with pMD2.G and psPAX2 packaging vectors (http://tronolab.epfl.ch/lentivectors). Where indicated,
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cells were infected using amphotropic retrovirus produced by transfection of pBABE vectors into
Phoenix packaging cells (https://web.stanford.edu/group/nolan/protocols/pro_optimiz.html). pBabe-
puro-RasV12 and pBABE-hygro-Trp53DD were a kind gift from Bob Weinberg (Addgene plasmids #
1768, # 9058) (Hahn et al., 2002), pBABE-puro-SV40-LT was a kind gift from Thomas Roberts
(Addgene plasmid # 13970) (Zhao et al., 2003).
Primary antibodies were used, unless indicated otherwise, at a dilution of 1:1000 for immunoblot-
ting and 1:200 for immunofluorescence. Secondary antibodies were used at a dilution of 1:10,000
for immunoblotting (LI-COR Biosciences) and 1:500 for immunofluorescence (Alexa Fluor, Life
Technologies)
The following antibodies were used: p44/42 MAPK (ERK1/2) (1:3000) (Cell Signaling), phospho-
p44/42 (ERK1/2) (Thr202/Tyr204) (Cell Signaling), GAPDH (1D4) (Novus Biologicals), Rock1 (H-85)
(Santa Cruz Biotechnology), Rock2 (ROKa) (BD Biosciences), phospho-MLC (Thr18/Ser19) (Cell Sig-
naling), phospho-MLC (Ser19) for immunofluorescence (Cell Signaling), MRCL3/MRLC2/MYL9 clone
(E-4) (Santa Cruz Biotechnology), p21/CIP1 (M-19) (Santa Cruz Biotechnology), Cks1 (Invitrogen),
p34cdc2 (Invitrogen), Cdc2 (Y15) (Cell Signaling), CyclinA (CY-A1) (Sigma Aldrich)
Inhibitors used were H1152 (Calbiochem/Merck Millipore), GSK429286A (Selleckchem),
GSK269962A (Axon Medchem), chroman1 (ApexBio), Blebbistatin + and Blebbistatin +/- (Calbio-
chem/Merck Millipore), nocodazole (Sigma Aldrich), AT13148 was synthesized in-house (Yap et al.,
2012b).
Immunofluorescence and microscopy
Cells were seeded on glass coverslips, or inside a 1.8 mg/ml collagen gel layer prepared according
to manufacturer’s instructions (PureCol, Advanced Biomatrix), and left to set in 1 m-slide chambers
(ibidi). The cells were then fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100
and blocked with 2% BSA before staining with phospho-MLC (Ser19) (Cell Signaling) and F-actin
(Phalloidin; Life Technologies) and mounting in Vectashield Hardset mounting medium containing
DAPI. Confocal images were acquired using a Zeiss LSM 710 microscope (40x oil immersion
objective).
Time-lapse phase-contrast microscopy was performed in a humidified CO2 chamber under a Dia-
phot inverted microscope (Nikon, UK) with a motorized stage (Prior Scientific, UK) controlled by Sim-
ple PCI software (Compix). Cells were monitored by taking an image every 10 min over a period of
16–24 hr and their division quantified. For analysis of cell motility, cells were tracked using ImageJ
analysis software (http://rsb.info.nih.gov/ij) and the ibidi chemotaxis and migration tool (www.ibidi.
com) used to determine migration speed (in mm/min) and directionality (displacement/track length,
where displacement is the distance from the start to end point for each cell) were determined using
ImageJ analysis software (http://rsb.info.nih.gov/ij) and ibidi chemotaxis and migration tool (www.
ibidi.com).
Immunoblot analysis
Cells were grown to approximately 80% confluence, washed once in PBS and lysed in SDS loading
buffer (100 mM Tris pH 6.8, 10% Glycerol, 2% SDS, [100 mM DTT]), homogenized by sonication for
5 s and boiled for 10 min. DTT, to a final concentration of 100 mM, was added after measuring pro-
tein concentration by Pierce BCA Assay (Thermo Scientific) and before boiling. Cell lysates contain-
ing equal amounts of protein were resolved by SDS-PAGE on precast NuPAGE Novex 10% Bis-Tris
Midi Protein Gels (Life Technologies) and transferred onto PVDF-FL membranes (Millipore). Mem-
branes were incubated with indicated antibodies and visualized by fluorescently conjugated second-
ary antibodies using the Odyssey Infrared Imaging System (LI-COR Biotechnology, Cambridge, UK).
Gel contraction assay
A total of 1x106 cells were embedded in 500 ml of a bovine Collagen I mix prepared according to
the manufacturer’s protocol (PureCol, Advanced Biomatrix) with a final concentration of approxi-
mately 2.1 mg/ml in a 24-well plate format. The gel was incubated at 37˚C for 1 hr for it to polymer-
ize and 500 ml of medium, containing inhibitors where indicated, was added. A pipette tip was then
used to loosen the gel from the tissue culture vessel and incubated for 16 hr. The plates were
scanned and percentage contraction was calculated by using the formula 100-([area of the gel/area
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of an empty well]*100) of which areas were determined using ImageJ software (http://rsbweb.nih.
gov/ij/) (Hooper et al., 2010).
Flow cytometry
Cells were fixed in ice-cold 70% ethanol for at least 1 hr at 4˚C and washed twice with PBS. DNA
was stained with propidium iodide (PI) (Sigma Aldrich) at a concentration of 20 mg/ml and in the
presence of 100 mg/ml RNaseA (Qiagen). The samples were analyzed on a BD LSR II flow cytometer
using BD FACSDiva software (BD Biosciences). Where indicated, cells were treated with
Nocodazole.
SA-bgal assay in vitro and in vivo
Staining to detect senescence-associated beta-galactosidase (SA-bgal) activity was carried out as
described by Debacq-Chainiaux et al. (Debacq-Chainiaux et al., 2009). For in vivo staining, the
mouse melanoma cell line (690cl2) used was generated from tumors arising in mice carrying
BrafV600E, Ptenf/f, Tyr-CreERT2after induction by Tamoxifen treatment (Dhomen et al., 2009). 2x105
melanoma cells were injected intra-dermally into the lateral flanks of 6–8 week-old CD1 athymic
mice; two days after injection the mice were randomly divided into two groups (three mice in each
group), one group was treated with vehicle only and the other with the drug. AT13148 was adminis-
tered at 40 mg/kg in 10% DMSO, 1% Tween-20 in saline, p.o., the dosing schedule used was 2/5
days. At the end of the experiment, the tumors were removed, snap-frozen and senescence-associ-
ated beta-galactosidase activity assessed on frozen sections using the protocol described above.
Mass spectrometry
SILAC heavy and light labelled MEFs were treated for indicated times with H1152, or vehicle, in
duplicate (heavy vs. light as well as light vs. heavy). Cells were then lysed by 2% SDS, Tris-HCl pH
7.5, and protein concentrations were measured and balanced by BCA assay. The reciprocal labels of
drug and vehicle treated lysates were then mixed 1:1, resulting in two reciprocally labelled SILAC
replicates (Heavy drug + light vehicle and vice versa). The mixed lysates were then reduced by addi-
tion of 100 mM DTT and boiling for 5 min, followed by trypsin digestion using a Filter Aided Sample
Preparation (FASP) protocol (Wisniewski et al., 2009). For phospho-peptide analysis, the digests
were subjected to phospho-peptide enrichment on TiO2 tips (GL sciences). For total proteome anal-
ysis, the digests were initially fractionated by isoelectric focusing, using an OFF-gel fractionator (Agi-
lent, pH 3–10). The fractions were then cleaned up using C18 ziptip columns (Millipore). All samples
were analyzed by LC-MS/MS using a Thermo Orbitrap-Velos mass spectrometer (ICR proteomics
core facility). The raw data wereas then searched and quantified using Maxquant (Cox and Mann,
2008). All subsequent statistical analysis was performed using Perseus software from the Maxquant
package. Briefly, the ratios were converted to Log-2 scale, and reverse and contaminants were fil-
tered out. Proteins only identified in one replicate were also filtered out. The ‘Significant-B’ outlier
test was used to determine the significantly regulated peptides or proteins, using a Benjamini-Hoch-
berg FDR rate of 5%. A hit was considered significant if it was found to be significantly changing in
opposite directions in both reciprocal SILAC replicates. 2-Dimensional Annotation enrichment analy-
sis was also performed in Perseus, using Broad Institute’s Gene Set Enrichment Analysis (GSEA)
annotations, using a Benjamini-Hochberg FDR rate of 2%. All proteomics data graphs were gener-
ated in Perseus. The targeted proteomics dataset has been deposited to PRIDE: Figure 4A
accession PXD002521, Figure 2—figure supplement 1B–C accession PXD002515.
Quantitative PCR
RNA was isolated using the RNeasy Mini Kit (Qiagen), according to manufaturer’s instructions, and
QuantiTect Primer Assays, purchased from Qiagen, were used. The Brilliant II SYBR Green QRT-PCR
1-Step system was used according to the manufacturer’s instructions (Agilent Technologies). The
reactions were analysed on an ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems).
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Absolute protein level quantitation by selected reaction monitoring
A previously reported approach for absolute quantitation of proteins (AQUA) based on standard sta-
ble isotope labelled peptides was used (Gerber et al., 2003). ‘Heavy’ isotopic peptides were pur-
chased from Thermo Scientific (USA). SRM was performed, as described elsewhere (Worboys et al.,
2014), for the measurement of endogenous and synthetic peptides. To select optimal proteotypic
peptides to monitor by SRM, all possible proteotypic peptides of ROCK1 and 2 were empirically
measured within cell lines that were wt, Rock1-/- and Rock2-/-, permitting a confirmation of peptide
specificity. For each SRM analysis bands from an SDS-PAGE gel were excised between 150–250 kDa
(Precision Plus Protein Prestained Standard, Bio-Rad), and proteins trypsin-digested in-gel.
NIDNFLSR, LLLQNELK and ESDIEQLR were chosen for ROCK1 and VYYDISSAK, QLDEANALLR and
ENLLLSDSPPCR for ROCK2. For quantitation, the two most intense transitions from each peptide
were summed for each isotopic variant. A cycle time of 1.8 s was used, and transitions monitored in
an unscheduled manner giving a dwell time of 37.5 ms. Standard curves were generated within sam-
ple matrices, and plotted as a function of their SILAC ratios. Subsequent regression lines were used
per peptide to calculate absolute concentrations. In tumor samples, 5 fmol of each peptide was
spiked into each sample. Three technical replicates were performed and averaged per peptide and
each average peptide measurement was averaged per protein. Thus, for each protein a total of 9
measurements are made. The targeted proteomics dataset has been deposited to the PeptideAtlas
SRM Experiment Library (PASSEL) with the identifier PASS00721.
Statistical analysis
Statistical tests were conducted with GraphPad Prism version 6 or Microsoft Excel 2010. Unless
stated otherwise, p-values were generated using two-tailed, paired Student’s t-test and considered
significant if p<0.05. * p<0.05; ** p<0.01 *** p<0.001. Error bars represent standard deviation (SD)
or standard error of the mean (SEM) as indicated in figure legends.
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